IN8bio(INAB) - 2025 Q1 - Quarterly Results

Exhibit 99.1 IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights Upcoming oral presentation: "INB-200: Phase 1 Study of Gene-Modified Autologous Gamma-Delta (γδ) T Cells in Newly Diagnosed Glioblastoma Multiforme (GBM) Patients • Presented new preclinical data at the 2025 American Association for Cancer Research (AACR) Annual Meeting highlighting the INB-600 platform, including lead candidates INB- 619 (targeting CD19) and INB-633 (targeting CD33). • Preclinical studies demons ...